TECHNETIUM TC-99M PENTETATE KIT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for TECHNETIUM TC-99M PENTETATE KIT (TECHNETIUM TC-99M PENTETATE KIT).
Technetium-99m pentetate is a radiopharmaceutical that, after intravenous administration, distributes in the extracellular space and is excreted by glomerular filtration. It is used to assess renal function and for imaging. The Tc-99m label emits gamma rays for detection.
| Metabolism | Tc-99m pentetate is not metabolized; it is eliminated unchanged by glomerular filtration. |
| Excretion | Primarily renal; 90-95% of injected dose excreted unchanged in urine within 24 hours via glomerular filtration. Minimal biliary/fecal elimination (<5%). |
| Half-life | 1.9 hours (terminal elimination half-life). Clinically, effective half-life is ~6 hours due to physical decay of Tc-99m (t½ 6.02 h) combined with biological clearance. |
| Protein binding | Negligible; approximately <5% bound to plasma proteins (albumin). |
| Volume of Distribution | 0.2-0.3 L/kg, corresponding to extracellular fluid volume in adults. Higher in neonates due to larger extracellular space. |
| Bioavailability | 100% after IV administration (only route used). Not administered orally or by other routes. |
| Onset of Action | After IV injection: rapid distribution to extracellular fluid; imaging of kidneys can begin within 1-3 minutes. Peak renal activity at 3-5 minutes. |
| Duration of Action | Renal imaging adequate for up to 1-2 hours. Effective imaging window is limited by physical half-life (6 hours). No pharmacological effect. |
Intravenous administration of 3-10 mCi (111-370 MBq) for renal imaging in adults. For cerebrospinal fluid (CSF) imaging, 0.5-2 mCi (18.5-74 MBq) intrathecally.
| Dosage form | INJECTABLE |
| Renal impairment | No specific GFR-based dose modifications required as technetium Tc-99m pentetate is used for renal function assessment; dose may be reduced in severe renal impairment (GFR <30 mL/min) to minimize radiation exposure, typically using 2-5 mCi IV. |
| Liver impairment | No specific Child-Pugh based modifications; hepatic dysfunction does not significantly affect clearance of this hydrophilic agent. |
| Pediatric use | Weight-based dose: 0.1-0.2 mCi/kg (3.7-7.4 MBq/kg) IV for renal imaging; minimum dose 0.5 mCi (18.5 MBq). For CSF imaging, 0.1-0.5 mCi (3.7-18.5 MBq) intrathecally adjusted for body size. |
| Geriatric use | No specific dose adjustment required; consider reduced renal function with age and use the lowest effective dose to achieve diagnostic quality, typically 3-5 mCi IV for renal imaging. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for TECHNETIUM TC-99M PENTETATE KIT (TECHNETIUM TC-99M PENTETATE KIT).
| Breastfeeding | Breastfeeding should be interrupted after administration. Tc-99m pentetate is excreted in breast milk. The milk-to-plasma (M/P) ratio is not well established. For Tc-99m compounds, typical radiation dose to infant is low but depends on radiopharmaceutical. Advise pumping and discarding milk for at least 4 hours (or one half-life of Tc-99m: 6 hours) to reduce exposure. Consult nuclear medicine guidelines. |
| Teratogenic Risk | Technetium Tc-99m pentetate is a radiopharmaceutical. Radiation exposure from diagnostic doses (typically <5 mSv) is below the threshold for deterministic fetal effects (100 mGy). However, theoretical stochastic risks exist. First trimester: Avoid unless benefit outweighs risk; organogenesis risk is highest. Second/third trimesters: Risk decreases but fetal thyroid uptake of free pertechnetate may occur. No known teratogenicity in animal studies. Use only if essential. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to technetium-99m pentetate or any component of the kit","Pregnancy (relative; only if benefit outweighs risk)"]
| Precautions | ["Risk of hypersensitivity reactions including anaphylaxis","Hydration before and after administration to reduce renal radiation dose","Consideration of radiation exposure in pregnant and breastfeeding women","Use in patients with renal impairment may prolong radiation exposure"] |
Loading safety data…
| Fetal Monitoring | No specific maternal-fetal monitoring required beyond standard radiation safety. Ensure adequate hydration to promote renal clearance. Monitor for allergic reactions (rare). Fetal radiation dose should be estimated (typically 0.004-0.02 mGy/MBq for early pregnancy; lower later). |
| Fertility Effects | No known effects on human fertility. Animal studies not fully evaluated. Radiation doses are diagnostic and well below levels associated with gonadal damage. |